# Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer

> **NCT06702995** · PHASE1,PHASE2 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 307 (estimated)

## Conditions studied

- Metastatic Castrate-Resistant Prostate Cancer
- mCRPC (Metastatic Castration-resistant Prostate Cancer)

## Interventions

- **DRUG:** XNW5004
- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT06702995
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-05-13
- **Final completion:** 2026-07-19
- **Target enrollment:** 307 (ESTIMATED)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06702995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06702995, "Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06702995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*